Literature DB >> 22565115

Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome.

Tor Seldén1, Johan Ahlner, Henrik Druid, Robert Kronstrand.   

Abstract

Buprenorphine is considered to have little respiratory side effects at therapeutic doses and the partial agonistic properties should produce a "ceiling effect" for respiratory depression at higher doses. Still, there are several reports on buprenorphine related deaths. Most deaths involve drug users and the co-administration of other CNS depressant drugs as well as reduced tolerance have been suggested to be risk factors. The primary aims were to investigate if lack of tolerance and/or co-ingestion of other psychotropic drugs are significant risk factors in buprenorphine fatalities. From July 2005 to September 2009, all autopsy cases where buprenorphine or norbuprenorphine had been detected in femoral blood and where analysis of buprenorphine had been performed in urine were selected. Results from the postmortem examination and toxicology were compiled. Postmortem toxicology was performed using the routine methodology at the laboratory. In total, 97 subjects were included in the study. These were divided into four groups; Intoxication with buprenorphine (N=41), Possible intoxication with buprenorphine (N=24), Control cases where buprenorphine was not the cause of death (N=14), and Unclear (N=18). The metabolite to parent compound ratios in both blood and urine in the Intoxication group were significantly different from those in the Control and Unclear groups. An extensive poly-drug use was seen in all groups with several additional opioids in the Possible group (54%) and in the Unclear group (78%) and hypnotics or sedatives in more than 75% of the Intoxication, Possible, and Unclear cases. Illicit drugs were present in all groups but not to a great extent with amphetamine and tetrahydrocannabinol as the main findings. Interestingly, 4 cases in the Intoxication group presented with no other significant drugs in blood other than buprenorphine. We conclude that a lethal concentration of buprenorphine in blood cannot be defined. Instead the analysis of blood as well as urine can be an important tool to show that the drug was taken shortly before death and to rule out a continuous use of buprenorphine supporting the notion that abstinence is an important risk factor. The presence of alprazolam in more than 40% of the Intoxications and the presence of hypnotics and sedatives in 75% of the Intoxications suggests that these drugs interact with buprenorphine producing toxic effects that buprenorphine alone would not have produced. Still, in 10% of the Intoxications no other drugs were found indicating that under certain circumstances buprenorphine alone may produce respiratory depression resulting in death.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22565115     DOI: 10.1016/j.forsciint.2012.03.016

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  12 in total

Review 1.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

2.  Buprenorphine treatment for narcotic addiction: not without risks.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

3.  Toxicological testing when evaluating fatal cases suspected of acute fentanyl toxicity.

Authors:  Xiulu Ruan; Srinivas Chiravuri; Alan D Kaye
Journal:  Forensic Sci Med Pathol       Date:  2016-07-07       Impact factor: 2.007

4.  Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.

Authors:  Zoe M Weinstein; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong Kim; Gabriela Gryczynski; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2016-11-05       Impact factor: 4.492

5.  Parent and Metabolite Opioid Drug Concentrations in Unintentional Deaths Involving Opioid and Benzodiazepine Combinations.

Authors:  Marcia D Fields; Marie A Abate; Lan Hu; D Leann Long; Matthew L Blommel; Nabila A Haikal; James C Kraner
Journal:  J Forensic Sci       Date:  2015-07       Impact factor: 1.832

6.  Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.

Authors:  Andrew Rosenblum; Ricardo A Cruciani; Eric C Strain; Charles M Cleland; Herman Joseph; Stephen Magura; Lisa A Marsch; Laura F McNicholas; Seddon R Savage; Arun Sundaram; Russell K Portenoy
Journal:  J Opioid Manag       Date:  2012 Nov-Dec

Review 7.  A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.

Authors:  Michelle R Lofwall; Sharon L Walsh
Journal:  J Addict Med       Date:  2014 Sep-Oct       Impact factor: 3.702

Review 8.  Postmortem Toxicology of New Synthetic Opioids.

Authors:  Marta Concheiro; Rachel Chesser; Justine Pardi; Gail Cooper
Journal:  Front Pharmacol       Date:  2018-10-26       Impact factor: 5.810

9.  Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.

Authors:  Björn Johnson; Torkel Richert
Journal:  Harm Reduct J       Date:  2019-05-02

10.  Opioid Overdose Deaths with Buprenorphine Detected in Postmortem Toxicology: a Retrospective Analysis.

Authors:  Rachel S Wightman; Jeanmarie Perrone; Rachel Scagos; Maxwell Krieger; Lewis S Nelson; Brandon D L Marshall
Journal:  J Med Toxicol       Date:  2020-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.